Erik Wennerberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erik Wennerberg has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Sandra Demaria
3 shared publicationsAdil Daud
University of California, San Francisco
2 shared publicationsAkos Savolt
Center of Oncosurgery, National Institute of Oncology, Budapest, Hungary
2 shared publicationsAlan Frey
Department of Cell Biology, School of Medicine, New York University, New York, NY, 10016, USA
2 shared publicationsAlan J. Korman
Bristol-Myers Squibb Company, Redwood City, CA, USA
2 shared publicationsAlexander L. Rakhmilevich
Dept. of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
2 shared publications
Latest Publications
- 1 January 2020
- Published by Elsevier
- Vol. 635, 139-148
Characterization of conventional dendritic cell populations in preclinical tumor models using flow cytometry
- 1 January 2020
- Published by Elsevier
- Vol. 635, 139-148
Characterization of conventional dendritic cell populations in preclinical tumor models using flow cytometry
- 1 March 2019
- Published by Elsevier in Trends in Cancer
- Vol. 5 (3) , 143-145
Born to Kill: NK Cells Go to War against Cancer
- 1 March 2019
- Published by Elsevier in Trends in Cancer
- Vol. 5 (3) , 143-145
Born to Kill: NK Cells Go to War against Cancer
- Open Access
- 19 September 2017
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1) , 73
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Background Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting factor in patients with solid tumors is defective homing of the infused NK cells to the tumor site. Chemokines regulate the migration of leukocytes expressing corresponding chemokine receptors. Various solid tumors, including renal cell carcinoma (RCC), readily secrete ligands for the chemokine receptor CXCR2. We hypothesize that infusion of NK cells expressing high levels of the CXCR2 chemokine receptor will result in increased influx of the transferred NK cells into tumors, and improved clinical outcome in patients with cancer. Methods Blood and tumor biopsies from 14 primary RCC patients were assessed by flow cytometry and chemokine analysis. Primary NK cells were transduced with human CXCR2 using a retroviral system. CXCR2 receptor functionality was determined by Calcium flux and NK cell migration was evaluated in transwell assays. Results We detected higher concentrations of CXCR2 ligands in tumors compared with plasma of RCC patients. In addition, CXCL5 levels correlated with the intratumoral infiltration of CXCR2-positive NK cells. However, tumor-infiltrating NK cells from RCC patients expressed lower CXCR2 compared with peripheral blood NK cells. Moreover, healthy donor NK cells rapidly lost their CXCR2 expression upon in vitro culture and expansion. Genetic modification of human primary NK cells to re-express CXCR2 improved their ability to specifically migrate along a chemokine gradient of recombinant CXCR2 ligands or RCC tumor supernatants compared with controls. The enhanced trafficking resulted in increased killing of target cells. In addition, while their functionality remained unchanged compared with control NK cells, CXCR2-transduced NK cells obtained increased adhesion properties and formed more conjugates with target cells. Conclusions To increase the success of NK cell-based therapies of solid tumors, it is of great importance to promote their homing to the tumor site. In this study, we show that stable engineering of human primary NK cells to express a chemokine receptor thereby enhancing their migration is a promising strategy to improve anti-tumor responses following adoptive transfer of NK cells.
- 19 September 2017
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1) , 73
Open AccessGenetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Background Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting factor in patients with solid tumors is defective homing of the infused NK cells to the tumor site. Chemokines regulate the migration of leukocytes expressing corresponding chemokine receptors. Various solid tumors, including renal cell carcinoma (RCC), readily secrete ligands for the chemokine receptor CXCR2. We hypothesize that infusion of NK cells expressing high levels of the CXCR2 chemokine receptor will result in increased influx of the transferred NK cells into tumors, and improved clinical outcome in patients with cancer. Methods Blood and tumor biopsies from 14 primary RCC patients were assessed by flow cytometry and chemokine analysis. Primary NK cells were transduced with human CXCR2 using a retroviral system. CXCR2 receptor functionality was determined by Calcium flux and NK cell migration was evaluated in transwell assays. Results We detected higher concentrations of CXCR2 ligands in tumors compared with plasma of RCC patients. In addition, CXCL5 levels correlated with the intratumoral infiltration of CXCR2-positive NK cells. However, tumor-infiltrating NK cells from RCC patients expressed lower CXCR2 compared with peripheral blood NK cells. Moreover, healthy donor NK cells rapidly lost their CXCR2 expression upon in vitro culture and expansion. Genetic modification of human primary NK cells to re-express CXCR2 improved their ability to specifically migrate along a chemokine gradient of recombinant CXCR2 ligands or RCC tumor supernatants compared with controls. The enhanced trafficking resulted in increased killing of target cells. In addition, while their functionality remained unchanged compared with control NK cells, CXCR2-transduced NK cells obtained increased adhesion properties and formed more conjugates with target cells. Conclusions To increase the success of NK cell-based therapies of solid tumors, it is of great importance to promote their homing to the tumor site. In this study, we show that stable engineering of human primary NK cells to express a chemokine receptor thereby enhancing their migration is a promising strategy to improve anti-tumor responses following adoptive transfer of NK cells.
- Open Access
- 16 January 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (S1) , 1-14
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
- 16 January 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (S1) , 1-14
Open AccessImmunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
- Open Access
- 8 December 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (S2) , 91
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016
- 8 December 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (S2) , 91
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016
- Open Access
- 16 November 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (S1) , 73-221
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
- 16 November 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (S1) , 73-221
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two